A Phase I Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety, Efficacy and Pharmacokinetics Profiles of TSB-9-W1 in Pre-treated Patients With Metastatic Colorectal Cancer (mCRC)

Trial Profile

A Phase I Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety, Efficacy and Pharmacokinetics Profiles of TSB-9-W1 in Pre-treated Patients With Metastatic Colorectal Cancer (mCRC)

Suspended
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs TSB 9-W1 (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Jan 2018 Planned number of patients changed from 30 to 12.
    • 09 Jan 2018 Planned End Date changed from 1 Nov 2017 to 31 Dec 2018.
    • 09 Jan 2018 Planned primary completion date changed from 1 Nov 2017 to 31 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top